<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EVOCLIN- clindamycin phosphateÂ aerosol, foamÂ </strong><br>Prestium Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EVOCLIN Foam safely and effectively. See full prescribing information for EVOCLIN Foam.<br><br>EVOCLIN<span class="Sup">Â®</span> (clindamycin phosphate) Foam, 1%<br>For Topical Use<br>Initial U.S. Approval: 1970</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">EVOCLIN Foam is a lincosamide product indicated for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years and older. (<a href="#LINK_c990b4a1-94e0-4e4a-8e95-857a29615317">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>For topical use only; not for oral, ophthalmic, or intravaginal use. (<a href="#LINK_a76a3398-9ae8-4213-a2cc-0db4ee1af2e6">2</a>)</li>
<li>Apply EVOCLIN Foam once daily to affected areas. (<a href="#LINK_a76a3398-9ae8-4213-a2cc-0db4ee1af2e6">2</a>)</li>
<li>Flammable; avoid fire, flame and/or smoking during and immediately following application. (<a href="#LINK_a76a3398-9ae8-4213-a2cc-0db4ee1af2e6">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Foam containing 1% clindamycin as clindamycin phosphate. (<a href="#LINK_806111bd-cebd-4fc7-9b69-ffd82d36307a">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">EVOCLIN Foam is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>). (<a href="#LINK_22890974-3fa0-409a-91ce-231c20d278f1">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>: Clindamycin can cause severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, which may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of clindamycin. EVOCLIN Foam should be discontinued if significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#LINK_7eafab97-2b24-4eaf-bd23-99036aece372">5.1</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;1%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> including burning, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and dryness. (<a href="#LINK_456e343f-ddb2-42d4-a131-b021d35d07bd">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Prestium Pharma, Inc. at 1-866-897-5002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Irritation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Erythromycin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Neuromuscular Blocking Agents</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-10.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Instructions for Use</a></h2>
<h2><a href="#section-14.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin Irritation</span></a></h2>
<h2><a href="#section-14.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_c990b4a1-94e0-4e4a-8e95-857a29615317"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">EVOCLIN Foam is indicated for topical application in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years and older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_a76a3398-9ae8-4213-a2cc-0db4ee1af2e6"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">EVOCLIN Foam is for topical use only, and not for oral, ophthalmic, or intravaginal use.</p>
<p>Apply EVOCLIN Foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.</p>
<p>If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued.</p>
<p>The contents of EVOCLIN Foam are flammable; avoid fire, flame and/or smoking during and immediately following application.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_806111bd-cebd-4fc7-9b69-ffd82d36307a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">White to off-white thermolabile foam. Each gram of EVOCLIN Foam contains, as dispensed, 12 mg (1.2%) of clindamycin phosphate, equivalent to 10 mg (1%) of clindamycin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_22890974-3fa0-409a-91ce-231c20d278f1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">EVOCLIN Foam is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_4e68a95a-e569-47f4-b092-b26259c19ab8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7eafab97-2b24-4eaf-bd23-99036aece372"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></h2>
<p class="First">Systemic absorption of clindamycin has been demonstrated following topical use of this product. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of topical clindamycin. If significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, EVOCLIN Foam should be discontinued. [<span class="Italics">See Adverse Reactions (<a href="#LINK_727047f1-a0db-42cf-b1e1-b4fb385697c9">6.2</a>).</span>]</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> has occurred following oral or parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Studies indicate a toxin(s) produced by <span class="Italics">Clostridia</span> is one primary cause of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is usually characterized by severe persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and may be associated with the passage of blood and mucus. Stool cultures for <span class="Italics">Clostridium difficile</span> and stool assay for <span class="Italics">C. difficile</span> toxin may be helpful diagnostically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7caa357a-beee-4c29-86c8-965a7ab6cff5"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Irritation</h2>
<p class="First">EVOCLIN Foam can cause irritation. Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> thereapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating, or abrasive agents. If irritation or <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> occurs, clindamycin should be discontinued. </p>
<p>Avoid contact of EVOCLIN Foam with eyes, mouth, lips, other mucous membranes or areas of broken skin. If contact occurs, rinse thoroughly with water.</p>
<p>EVOCLIN Foam should be prescribed with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_d5ff0d18-a286-4e3e-a831-a1e0bf2210a5"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_456e343f-ddb2-42d4-a131-b021d35d07bd"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>A total of 439 subjects with mild to moderate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> were treated once daily for 12 weeks with EVOCLIN Foam.</p>
<p>The incidence of adverse reactions occurring in â‰¥1% of the subjects in clinical trials comparing EVOCLIN Foam, and its vehicle is presented in Table 1.</p>
<table>
<caption><span>Table 1: Adverse Reactions Occurring in â‰¥1% of Subjects</span></caption>
<col width="47%">
<col width="19%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <p class="First"><span class="Bold">Adverse Reactions</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Â <p class="First"><span class="Bold">Number (%) of Subjects</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top">Â </td>
<td class="Rrule" align="center" valign="top">Â <p class="First"><span class="Bold">EVOCLIN Foam</span></p>
</td>
<td class="Rrule" align="center" valign="top">Â <p class="First"><span class="Bold">Vehicle Foam</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <p class="First"><span class="Bold">N = 439</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First"><span class="Bold">N = 154</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">12 (3%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">1 (1%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First"><span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">Application site burning</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">27 (6%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">14 (9%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">5 (1%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">5 (3%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Application site dryness</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">4 (1%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">5 (3%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reaction</span>, not otherwise specified</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">3 (1%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <p class="First">4 (3%)</p>
</td>
</tr>
</tbody>
</table>
<p>In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to EVOCLIN Foam.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_727047f1-a0db-42cf-b1e1-b4fb385697c9"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of EVOCLIN Foam: <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span>, application site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site rash</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">pain of skin</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>), and hemorraghic <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, as well as gram-negative <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, have also been reported in association with the use of topical formulations of clindamycin. Orally and parenterally administered clindamycin have been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, which may end fatally.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_9ae39c65-e6e7-4791-8ba5-09799e841688"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_58a39a85-17b6-4065-bee2-0ad5729b20fc"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Erythromycin</h2>
<p class="First">EVOCLIN Foam should not be used in combination with topical or oral erythromycin-containing products due to possible antagonism to its clindamycin component. <span class="Italics">In vitro</span> studies have shown antagonism between these two antimicrobials. The clinical significance of this <span class="Italics">in vitro</span> antagonism is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df6a1069-1774-4ec7-a5b7-7f71533065f8"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Neuromuscular Blocking Agents</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, EVOCLIN Foam should be used with caution in patients receiving such agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_38892fd0-6745-4cf5-845c-4e717ee88f75"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_81e2fcd0-7bd9-4031-92ed-7e7a49a53add"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women treated with EVOCLIN Foam. EVOCLIN Foam should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus.</p>
<p>Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin phosphate, clindamycin hydrochloride and clindamycin palmitate hydrochloride. These studies revealed no evidence of fetal harm. The highest dose used in the rat and mouse <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies was equivalent to a clindamycin phosphate dose of 432 mg/kg. For a rat, this dose is 84 fold higher, and for a mouse 42 fold higher, than the anticipated human dose of clindamycin phosphate from EVOCLIN Foam based on a mg/m<span class="Sup">2</span> comparison.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_fda6ec4a-1824-4686-80ea-e3e45667e44d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether clindamycin is excreted in human milk following use of EVOCLIN Foam. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>If used during lactation and EVOCLIN Foam is applied to the chest, care should be taken to avoid accidental ingestion by the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_d59694d7-40a4-4dab-bc01-70ef693b2d12"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of EVOCLIN Foam in children under the age of 12 have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_5cf56f5c-1f19-4734-b01a-0c849f4b1e87"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The clinical study with EVOCLIN Foam did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_35146688-f1a9-4d5f-aec8-a05e49ec0f0a"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EVOCLIN (clindamycin phosphate) Foam contains clindamycin (1%) as clindamycin phosphate.</p>
<p>Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.</p>
<p>The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-Î±-D-<span class="Italics">galacto</span>-octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:</p>
<div class="Figure"><img alt="Clindamycin phosphate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-1.jpg"></div>
<p>Molecular Formula: C<span class="Sub">18</span>H<span class="Sub">34</span>ClN<span class="Sub">2</span>O<span class="Sub">8</span>PSÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Molecular Weight: 504.97 g/mol</p>
<p>EVOCLIN Foam contains clindamycin (1%) as clindamycin phosphate, at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol, ethanol (58%), polysorbate 60, potassium hydroxide, propylene glycol, purified water, and stearyl alcohol pressurized with a hydrocarbon (propane/butane) propellant.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_46c218ae-b94c-421d-abe3-f2a0058647d3"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9baa174-78d8-4ccc-8832-c3369717a041"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Mechanism of action in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> is unknown. <span class="Italics">[See Microbiology (<a href="#LINK_e57637b7-e4da-4854-b879-990a8023aa8c">12.4</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_664c911c-6787-42e3-a2c8-ba81d4fbf621"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Pharmacodynamics of EVOCLIN Foam is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ab4d9dbe-7cf4-4ee9-8f9e-d0a336fc4f44"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In an open label, parallel group study in 24 subjects with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>, 12 subjects (3 male and 9 female) applied 4 grams of EVOCLIN Foam once-daily for five days, and 12 subjects (7 male and 5 female) applied 4 grams of a clindamycin gel, 1%, once daily for five days. On Day 5, the mean C<span class="Sub">max</span> and AUC<span class="Sub">(0-12)</span> were 23% and 9% lower, respectively, for EVOCLIN Foam than for the clindamycin gel, 1%.</p>
<p>Following multiple applications of EVOCLIN Foam, less than 0.024% of the total dose was excreted unchanged in the urine over 12 hours on Day 5.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="LINK_e57637b7-e4da-4854-b879-990a8023aa8c"></a><a name="section-10.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">No microbiology studies were conducted in the clinical trials with this product.</p>
<p>Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Clindamycin has been shown to have <span class="Italics">in vitro</span> activity against <span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> (<span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span>), an organism that has been associated with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>; however, the clinical significance of this activity against <span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> was not examined in clinical studies with EVOCLIN Foam. <span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> resistance to clindamycin has been documented.</p>
<p><span class="Italics">Inducible Clindamycin Resistance</span></p>
<p>The treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> with antimicrobials is associated with the development of antimicrobial resistance in <span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span> </span>as well as other bacteria (e.g. <span class="Italics">Staphylococcus aureus, Streptococcus pyogenes</span>). The use of clindamycin may result in developing inducible resistance in these organisms. This resistance is not detected by routine susceptibility testing.</p>
<p><span class="Italics">Cross Resistance</span></p>
<p>Resistance to clindamycin is often associated with resistance to erythromycin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_eed4d6e1-423c-499b-bccf-13612eeed55e"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_fd0fc5fb-89fc-46d0-b7bd-99acbfe87b68"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The carcinogenicity of a 1.2% clindamycin phosphate gel similar to EVOCLIN Foam was evaluated by daily application to mice for two years. The daily doses used in this study were approximately 3 and 15 times higher than the human dose of clindamycin phosphate from 5 milliliters of EVOCLIN Foam, assuming complete absorption and based on a body surface area comparison. No significant increase in tumors was noted in the treated animals.</p>
<p>A 1.2% clindamycin phosphate gel similar to EVOCLIN Foam caused a statistically significant shortening of the median time to tumor onset in a study in hairless mice in which tumors were induced by exposure to simulated sunlight.</p>
<p>Genotoxicity tests performed included a rat micronucleus test and an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reversion test. Both tests were negative.</p>
<p>Reproduction studies in rats using oral doses of clindamycin hydrochloride and clindamycin palmitate hydrochloride have revealed no evidence of impaired fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_b1e07c53-8115-4c56-859a-43ba37412676"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In one multicenter, randomized, double-blind, vehicle-controlled clinical trial, subjects with mild to moderate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> used EVOCLIN Foam or the vehicle Foam once daily for twelve weeks. Treatment response, defined as the proportion of subjects clear or almost clear, based on the Investigator Static Global Assessment (ISGA), and the mean percent reductions in lesion counts at the end of treatment in this study are shown in Table 2.</p>
<table>
<caption><span>Table 2: Efficacy Results at Week 12</span></caption>
<col width="28%">
<col width="19%">
<col width="16%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>P &lt; 0.05</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <p class="First"><span class="Bold">Efficacy Parameters</span></p>
</td>
<td class="Botrule Rrule Toprule" valign="top">Â <p class="First"><span class="Bold">EVOCLIN Foam</span></p>
<p><span class="Bold">N=386</span></p>
</td>
<td class="Botrule Rrule Toprule" valign="top">Â <p class="First"><span class="Bold">Vehicle Foam</span></p>
<p><span class="Bold">N=127</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Treatment response (ISGA)</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">31%</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">18%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3" valign="top">Â <p class="First"><span class="Bold">Percent reduction in lesion counts</span></p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Inflammatory Lesions</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">49%</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">35%<a href="#footnote-1" class="Sup">*</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Noninflammatory Lesions</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">38%</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">27%<a href="#footnote-1" class="Sup">*</a></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â <p class="First">Total Lesions</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">43%</p>
</td>
<td class="Botrule Rrule" valign="top">Â <p class="First">31%<a href="#footnote-1" class="Sup">*</a></p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_49e7b43d-0b1b-4809-a709-a6d900d416c4"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f013fb4-8a19-4c9d-8e5d-579a6c656f94"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Evoclin (clindamycin phosphate) Foam, 1% is supplied as follows:</p>
<ul class="Disk">
<li>50 g aluminum canÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 40076-061-50</li>
<li>100 g aluminum canÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â NDC 40076-061-00</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a3927cc5-611e-46ae-b668-4ef602a5e152"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at controlled room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</p>
<p>Flammable. Avoid fire, flame or smoking during and immediately following application.</p>
<p>Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperature above 120Â°F (49Â°C).</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_56e42f14-858a-49ca-abe0-ea456c872c8c"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved patient labeling (Patient Information).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7ce1621-4a42-4b3b-a6ac-249f2f9744ed"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Instructions for Use</h2>
<ul class="Disk">
<li>Patients should be advised to wash their skin with mild soap and allow it to dry before applying EVOCLIN Foam.</li>
<li>Patients should use enough EVOCLIN Foam to cover the face and to apply once daily.</li>
<li>Patients should dispense EVOCLIN Foam directly into the cap or onto a cool surface.</li>
<li>Patients should wash their hands after applying EVOCLIN Foam.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ce61ec11-03fa-492c-a2c3-ade223be5bc5"></a><a name="section-14.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin Irritation</span></h2>
<p class="First">EVOCLIN Foam may cause irritation such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. Patients should be advised to discontinue use if excessive irritancy or <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_664ed814-d882-494f-beb3-832d34bff126"></a><a name="section-14.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></h2>
<p class="First">In the event a patient treated with EVOCLIN Foam experiences severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span>, EVOCLIN Foam should be discontinued and a physician should be contacted.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_59f679a5-d159-48e9-9935-eaa213c525a8"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information<br></span><span class="Bold">EVOCLIN (Ev-o-clin) <br></span><span class="Bold">(clindamycin phosphate) Foam</span></p>
<table width="0px">
<col width="0px">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" colspan="2">
<span class="Bold">Important: </span><span class="Bold">For skin use only. Do not use EVOCLIN Foam in your eyes, mouth or vagina.</span>
</td></tr></tbody>
</table>
<p>Read the Patient Information that comes with EVOCLIN Foam before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is EVOCLIN Foam?</span></p>
<p>EVOCLIN Foam is a prescription medicine used on the skin (topical) to treat <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in people 12 years and older.</p>
<p>It is not known if EVOCLIN Foam is safe and effective in children under 12 years of age.</p>
<p><span class="Bold">Who should not use EVOCLIN Foam?</span></p>
<p><span class="Italics">Do not use EVOCLIN Foam if you:</span></p>
<ul class="Disk">
<li>have Crohnâ€™s disease</li>
<li>have <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span></li>
<li>have had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the colon (<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>) or severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with past antibiotic use</li>
</ul>
<p>Tell your doctor if you are not sure if you have any of the conditions listed above.</p>
<p><span class="Bold">What should I tell my doctor before using EVOCLIN Foam?</span></p>
<p><span class="Bold">Before you use EVOCLIN Foam, tell your doctor if you:</span></p>
<ul class="Disk">
<li>have a history of <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span></li>
<li>are planning to have surgery. EVOCLIN Foam may affect how certain medicines work that may be given during surgery.</li>
<li>have any other medical conditions</li>
<li>are pregnant or planning to become pregnant. It is not known if EVOCLIN Foam may harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if EVOCLIN Foam passes through your breast milk. You and your doctor should decide if you will use EVOCLIN Foam or breastfeed. If you use EVOCLIN Foam while breastfeeding and EVOCLIN Foam is applied on the chest, take care to avoid getting EVOCLIN Foam into your babyâ€™s mouth.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and non-prescription medicines, vitamins and herbal supplements. EVOCLIN Foam may affect the way other medicines work and other medicines may affect how EVOCLIN Foam works.</p>
<p>Especially tell your doctor if you take erythromycin or use products on your skin that contain erythromycin. </p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I use EVOCLIN Foam?</span></p>
<ul class="Disk">
<li>EVOCLIN Foam is for use on the skin only. Do not get EVOCLIN Foam in your eyes, mouth or vagina.</li>
<li>Use EVOCLIN Foam exactly as your doctor tells you to use it. See the â€œInstructions for Applying EVOCLIN Foamâ€? below.</li>
<li>Apply EVOCLIN Foam 1 time a day.</li>
<li>Wash your skin with mild soap and water and dry before applying EVOCLIN Foam.</li>
<li>Do not dispense EVOCLIN Foam directly onto your hands or face, because the foam will begin to melt on contact with warm skin.</li>
</ul>
<p><span class="Bold">Instructions for Applying EVOCLIN Foam.</span></p>
<ul class="Disk"><li>Remove the clear cap from the EVOCLIN Foam can (See Figure A).</li></ul>
<div class="Figure"><img alt="Figure A: Remove Clear Cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-2.jpg"></div>
<p>Figure A: Remove clear cap.</p>
<ul class="Disk"><li>Line up the black circle with the nozzle (See Figure B).</li></ul>
<div class="Figure"><img alt="Figure B: Lione up the black circle with the nozzle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-3.jpg"></div>
<p>Figure B: Line up the black circle with the nozzle.</p>
<ul class="Disk"><li>Hold the can upright and firmly press the nozzle to dispense EVOCLIN Foam (See Figure C).</li></ul>
<div class="Figure"><img alt="Figure C: Hold can upright and press nozzle firmly to dispense" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-4.jpg"></div>
<p>Figure C: Hold can upright and press nozzle firmly to dispense.</p>
<p>Dispense EVOCLIN Foam into the clear cap or onto a cool surface (see Figure D).</p>
<div class="Figure"><img alt="Figure D: Dispense EVOCLIN Foam into clear cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-5.jpg"></div>
<p>Figure D: Dispense EVOCLIN Foam into clear cap.</p>
<ul class="Disk"><li>Dispense enough EVOCLIN Foam to cover the affected area (see Figure E).<div class="Figure"><img alt="Figure E: Dispense enough EVOCLIN Foam to cover affected area" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-6.jpg"></div>
</li></ul>
<p>Figure E: Dispense enough EVOCLIN Foam to cover affected area.</p>
<ul class="Disk"><li>If the can seems warm or the foam seems runny, run the can under <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water (See Figure F).</li></ul>
<div class="Figure"><img alt="Figure F: If the can seems warm or the foam is runny, run the can under <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-7.jpg"></div>
<p>Figure F: If the can seems warm or the foam is runny, run the can under <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water.</p>
<ul class="Disk"><li>Pick up small amounts of EVOCLIN Foam with your fingertips and gently rub the foam into the affected area until the foam disappears (See Figure G).</li></ul>
<div class="Figure"><img alt="Figure G: Pick up a small amount of EVOCLIN Foam on your fingertips and gently rub into the affected area until the foam disappears" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-8.jpg"></div>
<p>Figure G: Pick up a small amount of EVOCLIN Foam on your fingertips and gently rub into the affected area until the foam disappears.</p>
<ul class="Disk"><li>Wash your hands after applying EVOCLIN.</li></ul>
<p>Throw away any of the unused medicine that you dispensed out of the can.</p>
<p><span class="Bold">What should I avoid while using EVOCLIN Foam?</span></p>
<ul class="Disk">
<li>EVOCLIN Foam is flammable. Avoid fire, flames, or smoking during and right after you apply EVOCLIN Foam to your skin.</li>
<li>Avoid getting EVOCLIN Foam in or near your eyes, mouth, lips, or broken skin. If you get EVOCLIN Foam in your eyes, mouth, on lips or broken skin, rinse well with water.</li>
</ul>
<p><span class="Bold">What are possible side effects with EVOCLIN Foam?</span></p>
<p><span class="Bold">EVOCLIN Foam can cause serious side effects including:</span></p>
<ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the colon (<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>). Clindamycin can cause severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Stop using EVOCLIN Foam and call your doctor right away if you have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>.</li></ul>
<p>The most common side effects of EVOCLIN Foam include:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span>. EVOCLIN Foam may cause <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> such as burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or dryness. Stop using EVOCLIN Foam and talk with your doctor if you develop any excessive <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the side effects of EVOCLIN Foam. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may report side effects toÂ Prestium Pharma, Inc. at 1-866-897-5002.</p>
<p><span class="Bold">How should I store EVOCLIN Foam?</span></p>
<ul class="Disk">
<li>Store EVOCLIN Foam at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Keep EVOCLIN Foam away from heat. Never throw the can into a fire, even if the can is empty.</li>
<li>Do not store EVOCLIN Foam at temperatures above 120Â°F (49Â°C).</li>
<li>Do not break through (puncture) the EVOCLIN Foam can.</li>
</ul>
<p><span class="Bold">Keep EVOCLIN Foam and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of EVOCLIN Foam:</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do not use EVOCLIN Foam for a condition for which it was not prescribed. Do not give EVOCLIN Foam to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about EVOCLIN Foam. If you would like more information, talk with your doctor. You can also ask your pharmacist or doctor for information about EVOCLIN Foam that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in EVOCLIN Foam?</span></p>
<p>Active ingredient: clindamycin phosphate</p>
<p>Inactive ingredients: cetyl alcohol, ethanol (58%), polysorbate 60, potassium hydroxide, propylene glycol, purified water, and stearyl alcohol. The can is pressurized with a hydrocarbon (propane/butane) propellant.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:<br>Prestium Pharma, Inc.<br>Newtown, PA 18940<br>By DPT Laboratories, Ltd.<br>San Antonio, TX 78215</p>
<p>For additional information:<br>1-866-897-5002<br>Or visit</p>
<p>www.evoclin.com</p>
<p>EVOCLIN  is a registered trademark of Stiefel Laboratories, Inc.
<br>2013 Delcor Asset Corporation, an affiliate of Prestium Pharma, Inc.

<br><br>June 2013
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_4a006548-1c1b-4259-819b-12c3bfb946b7"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><span class="Bold">NDC 40076-061-50</span></p>
<p><span class="Bold">50 g</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">evoclin</span><span class="Sup">Â®</span><br>(clindamycin phosphate)<br>Foam, 1%</p>
<p><span class="Bold">FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.</span></p>
<p><span class="Bold">Description</span>: Evoclin<span class="Sup">Â®</span> (clindamycin phosphate) Foam 1%, contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol, ethanol (58%), polysorbate 60, potassium hydroxide, propylene glycol, purified water, and stearyl alcohol pressurized with a hydrocarbon (propane/butane) propellant.</p>
<p><span class="Bold">Dosage</span>: Use only as prescribed by your physician. See package insert for full prescribing information.</p>
<p><span class="Bold">Warning: FLAMMABLE. AVOID FIRE, FLAME, OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION.</span></p>
<p>Keep out of reach of children. Avoid contact with eyes.</p>
<p>Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120Â°F (49Â°C).</p>
<p>Store at controlled room temperature, 68Â°-77Â°F (20Â°-25Â°C).</p>
<p><span class="Bold">CFC FREE</span></p>
<p>Manufactured for:<br>Prestium Pharma, Inc.<br>Newtown, PA 18940<br>By DPT Laboratories, Ltd.<br>San Antonio, TX 78215</p>
<p>For additional information:<br>1-866-897-5002 or visit<br>www.evoclin.com</p>
<p>Â©2013Â Delcor Asset Corporation,<br>an affiliate of Prestium Pharma, Inc.</p>
<p>Evoclin is a registered trademark of Stiefel Laboratories, Inc.</p>
<div class="Figure"><img alt="Principal Display Panel NDC 40076-061-50 50 g Rx only evoclinÂ® (clindamycin phosphate) Foam, 1%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=daa3d9d1-c906-41f3-83a2-c47f2283da48&amp;name=evoclin-9.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EVOCLINÂ 		
					</strong><br><span class="contentTableReg">clindamycin phosphate aerosol, foam</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:40076-061</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN PHOSPHATE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN</td>
<td class="formItem">10Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 60</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:40076-061-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 g in 1 CAN</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:40076-061-00</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 CAN</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050801</td>
<td class="formItem">08/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Prestium Pharma, Inc.
							(078304674)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Denco Asset, LLC (965099505)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224526</td>
<td class="formItem">MANUFACTURE(40076-061)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91b5b266-63e2-4afb-a093-0142485018b8</div>
<div>Set id: daa3d9d1-c906-41f3-83a2-c47f2283da48</div>
<div>Version: 2</div>
<div>Effective Time: 20140819</div>
</div>
</div>Â <div class="DistributorName">Prestium Pharma, Inc.</div></p>
</body></html>
